Webinar: Strategies for In-House Counsel Selecting Trademarks for Pharmaceuticals and Biologics
Sponsored by Foley Hoag LLP
Naming pharmaceutical and biologic products presents unique challenges from both trademark and regulatory perspectives. In addition to the traditional marketing goals of trademark selection, companies evaluating names for medications must also consider safety issues, false advertising concerns, and more. Importantly, pharmaceutical trademarks must pass muster not only with the Patent and Trademark Office (PTO), but also with the Food and Drug Administration (FDA). The recent advent of a market for biosimilars presents new questions and challenges.
Foley Hoag presents a webinar offering guidance to in-house counsel on best practices for pharmaceutical and biologics companies in selecting, vetting, and seeking approval for medication product names. The focus will be primarily on the U.S. market, although foreign strategies may be addressed as well.
- Julia Huston Partner, Chair, Trademark, Copyright & Unfair Competition Practice, Foley Hoag LLP
- Areta Kupchyk, Partner, Foley Hoag LLP
- Jenevieve Maerker, Associate, Foley Hoag LLP
If you are in-house counsel and would like to receive a copy of the written materials containing talking points to accompany these slides, please contact us.